Rinvoq (upadacitinib), an oral therapy recently approved for rheumatoid arthritis, was effective in treating adults with active ankylosing spondylitis (AS) who failed to respond to or are not eligible for non-steroidal anti-inflammatory drugs (NSAIDs), a Phase 2/3 trial shows. After 14 weeks of treatment, taking daily…
Treatment with Cosentyx (secukinumab) provided stable reduction in disease activity, as well as less pain and better mobility in people with non-radiographic axial spondyloarthritis (nr-axSpA), a Phase 3 trial shows. Atul Deodhar, MD, the study’s lead investigator, presented the research in a session, “Secukinumab 150 mg Significantly…
Abrilada (adalimumab-afzb), a biosimilar to Humira (adalimumab), has been approved by the U.S. Food and Drug Administration (FDA) to treat people with seven inflammatory diseases, including adults with ankylosing spondylitis. Pfizer, the company that developed Abrilada, expects the therapy to be available in the U.S. starting in 2023.
Treatment with Erelzi (etanercept) is well-tolerated by people with ankylosing spondylitis (AS) and other rheumatic diseases, including rheumatoid arthritis (RA) and progressive psoriatic arthritis, an early analysis of a real-world study suggests. The findings also indicated that Erelzi reduced disease activity in patients with RA, the only group…
Rare disease-themed videos glowed on a large screen before an audience of people in wheelchairs, with crutches, and bearing oxygen tanks this Nov. 9 and 10 in San Francisco. Disorder: The Rare Disease Film Festival strives to eventually host a film about every one of the nearly 7,000 rare…
Biogen has signed an agreement with Samsung Bioepis that includes an option of extending commercialization rights to three biosimilars of TNF inhibitor therapies used for ankylosing spondylitis (AS) — Benepali (etanercept), Flixabi (infliximab), and Imraldi (adalimumab) — for an additional five years in Europe. The…
Treatment with the experimental therapy bimekizumab is safe and shows sustained efficacy over 48 weeks in people with ankylosing spondylitis (AS), data from a Phase 2b trial show. In addition, the use of biologic therapies for AS is associated with more comorbidities and higher use of other treatments…
Continuous use of non-steroidal anti-inflammatory drugs (NSAIDs) increases the risk of hypertension by 12% in people with ankylosing spondylitis (AS), a prospective study suggests. The study, “Nonsteroidal Anti-inflammatory Drug use is Associated with Incident Hypertension in Ankylosing Spondylitis,” was published in the journal Arthritis Care &…
Women with ankylosing spondylitis (AS) stay with TNF inhibitor treatment for significantly shorter periods than men, mostly due to ineffectiveness, and they are at higher risk of developing infections while on these biological therapies, according to real-world data from the Netherlands. The study, “Gender differences in retention rate of…
Gout —a common, painful form of arthritis that causes swollen, red, hot, and stiff joints — may be more common in people with ankylosing spondylitis (AS) than in the general population, a study suggests. Among people with AS, this association is particularly likely in patients ages 40-60,…
Get regular updates to your inbox.